Insulet Target Price

Analysts' average 12-month price target for Insulet is $180.

Get informed when a big investor buys or sells

+ Follow

Share Price

$149.01

Average Target Price

$179.00

20.1% upside

15 analysts in the last 4 months

High: $245 | Low: $144

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-10-12	JefferiesMatthew Taylor	$190	27.5% upside
2026-10-06	Barclays	$150	0.7% upside
2026-08-06	Robert W. BairdJeff Johnson	$175	17.4% upside
2026-08-06	Bernstein	$175	17.4% upside
2026-08-06	Leerink PartnersMike Kratky	$145	2.7% downside
2026-08-06	Raymond JamesJayson Bedford	$180	20.8% upside
2026-08-06	RBC Capital	$160	7.4% upside
2026-08-06	Canaccord GenuityWilliam Plovanic	$179	20.1% upside
2026-08-05	Wells FargoLarry Biegelsen	$144	3.4% downside
2026-08-05	Truist Financial	$153	2.7% upside
2026-07-28	UBS	$174	16.8% upside
2026-07-13	RBC Capital	$245	64.4% upside
2026-07-13	Truist Financial	$210	40.9% upside
2026-07-10	Stifel Nicolaus	$225	51% upside
2026-07-06	Evercore ISI	$180	20.8% upside
2026-06-23	Deutsche Bank	$190	27.5% upside
2026-06-11	UBS	$219	47% upside
2026-06-11	Truist FinancialRichard Newitter	$219	47% upside
2026-06-08	Raymond James	$216	45% upside
2026-05-27	Goldman SachsDavid Roman	$205	37.6% upside
2026-05-26	BTIG	$235	57.7% upside
2026-05-07	Goldman Sachs	$237	59% upside
2026-05-07	RBC CapitalShagun Singh	$280	87.9% upside
2026-05-07	Truist FinancialRichard Newitter	$250	67.8% upside
2026-05-07	Evercore ISI	$200	34.2% upside
2026-05-07	Oppenheimer	$210	40.9% upside
2026-05-07	Stifel Nicolaus	$250	67.8% upside
2026-05-07	Canaccord GenuityWilliam Plovanic	$249	67.1% upside
2026-05-07	Bernstein	$200	34.2% upside
2026-05-07	BarclaysMatt Miksic	$198	32.9% upside
2026-05-06	BTIG	$260	74.5% upside
2026-04-24	Redburn Partners	$220	47.6% upside
2026-04-15	Truist FinancialRichard Newitter	$315	111.4% upside
2026-04-14	RBC CapitalShagun Singh	$325	118.1% upside
2026-02-19	Truist Financial	$360	141.6% upside
2026-02-19	Evercore ISI	$340	128.2% upside
2026-02-19	Goldman SachsDavid Roman	$326	118.8% upside
2026-02-19	Oppenheimer	$300	101.3% upside
2026-02-19	Bernstein	$330	121.5% upside
2026-02-19	Barclays	$286	91.9% upside
2026-02-18	Canaccord GenuityWilliam Plovanic	$435	191.9% upside
2026-02-04	Stifel Nicolaus	$350	134.9% upside
2026-01-12	Barclays	$274	83.9% upside
2026-01-09	BernsteinLee Hambright	$380	155% upside
2026-01-09	Goldman SachsDavid Roman	$365	145% upside
2025-12-18	Truist Financial	$390	161.7% upside
2025-12-17	Canaccord Genuity	$450	202% upside
2025-12-16	Evercore ISI	$370	148.3% upside
2025-11-24	Canaccord Genuity	$432	189.9% upside
2025-11-21	Truist FinancialRichard Newitter	$412	176.5% upside

Insulet (PODD) FAQ

Insulet (PODD) currently reports a target price of $180. Use the charts on this page to explore Insulet's target price history and peer comparisons.

Analysts' average 12-month price target for Insulet is $180, about 20.1% upside from the current share price of $149.01. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $180, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Insulet, and consider following PODD for alerts when major investors trade the stock.

Insulet is classified in the Healthcare sector. On target price, it currently shows $180. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PODD with unrelated industries.